Navigation Links
Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
Date:1/28/2013

s, Mr. Aldridge held investment banking positions at leading international financial firms, including Wilson HTM Investment Group, Bear Stearns & Co., Volpe, Brown Whelan & Company, and SG Warburg Group.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor has also launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , September 4, 2015 ... announces that Hutchison MediPharma Limited ("HMP"), its drug ... the second proof-of-concept ("POC") trial of fruquintinib in ... ("NSCLC") in China .  The ... in meeting the primary efficacy endpoint of progression ...
(Date:9/3/2015)... , Sept. 3, 2015 ... of New Drugs, Industry Changes and Emerging Opportunities ... human ovaries? Visiongain,s new study forecasts those pharmaceutical ... in that industry. You also explore trends, results, ... Our report gives revenue predictions to 2025 at ...
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... – Your New Guide to that Market, its R&D and ... want to assess the future of cancer-treating medicines? Visiongain,s new ... helping you stay ahead. There you discover financial data, R&D ... In our analysis you see forecasted sales ...
Breaking Medicine Technology:Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine ... Mass., March 4 Decision Resources, one of the ... and healthcare issues, finds that second-line patient share of ... to 35.2 percent since last year,s report. Most of ...
... in Small, Ambulatory Physician PracticesSCHAUMBURG, Ill., March 3 ... Information Technology (CCHIT(R)), the federally recognized body for ... announced it will develop dermatology-specific functionality criteria beginning ... a response to an application from the American ...
Cached Medicine Technology:Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 2Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 3Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology 2
(Date:9/5/2015)... ... September 05, 2015 , ... "I have personally had three knee-replacement surgeries on ... Phoenix, Ariz. "I came up with this idea so that I could not only ... They developed the KNEE BUDDY to comfortably and safely support the knee while recovering ...
(Date:9/5/2015)... , ... September 05, 2015 , ... As school supply lists continue to increase and ... supply demands for their students. William Mattar Law Offices has found a way to ... to teachers as well as principals and superintendents as in past years. Because of ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article published August ... Association presented data showing that it is safe for pregnant women to undergo local ... had undergone local anesthesia with a group that hadn’t, researchers were able to determine ...
(Date:9/4/2015)... ... 04, 2015 , ... The Schmidt National Law Group filed an Essure® lawsuit ... Schmidt National Law Group, a leading firm in mass-tort litigation, has filed a lawsuit ... Essure, Inc., and other Bayer affiliates for injuries alleged to have been caused by ...
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms for six ... apparel. In an effort to assist the team, the Jones Agency, a locally owned ... to raise funds for the new uniforms. , As is so often the case ...
Breaking Medicine News(10 mins):Health News:InventHelp Inventor Develops Therapeutic Knee Support (PHO-2061) 2Health News:‘Pencils 4 Schools’ Campaign 2015 Exceeds Expectations from Previous Year 2Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3
... KePRO,s Chief Medical Officer recognized for commitment to improving patient care ... ... February 6, 2009 -- Alice Stollenwerk Petrulis , MD, FACP, ... Committee. Dr. Petrulis, a nationally recognized leader in health care quality ...
... MASI ), the inventor of Pulse CO-Oximetry(TM) ... that its management is scheduled to present at the ... at The Ritz-Carlton, Laguna Niguel in Dana Point, California, ... A live audiocast of the presentation will be available ...
... Hospitalized Veterans Co-Sponsors Concert Series in Support of National ... As Valentines Day approaches, thousands of Americans will look ... and significant others. Whether it,s a thoughtful gift or ... time with loved ones and showing them your appreciation. ...
... the first South Florida,publication dedicated to providing expert advice ... men and women, will host its sold-out, first,annual 5K ... The Sports,Club/LA, as part of the series of events ... On February 8th, 2009, hundreds of runners and ...
... and little encouragement for kids to be otherwise, , , ... playing outside, children tend not to be physically active ... fact, the researchers found that 89 percent of so-called ... be sedentary at community-based preschool programs, as were more ...
... should not immediately order routine scans for low-back pain ... researchers in the Oregon Evidence-Based Practice Center at Oregon ... in this week,s edition of the The Lancet ... CT scans in patients with low-back pain but no ...
Cached Medicine News:Health News:Alice Stollenwerk Petrulis, MD, FACP, Appointed to NQF Care Coordination Committee 2Health News:Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference 2Health News:Free 'Valentines for Veterans Concerts' Honor Veterans Across the Country 2Health News:Free 'Valentines for Veterans Concerts' Honor Veterans Across the Country 3Health News:SOBeFiT Magazine Promotes its Launch With First Annual 5K Run+Walk & Fitness Festival in South Beach 2Health News:SOBeFiT Magazine Promotes its Launch With First Annual 5K Run+Walk & Fitness Festival in South Beach 3Health News:For Preschoolers, Even 'Play' Tends to Be Sedentary 2Health News:Routine scans for low-back pain do not improve outcomes 2Health News:Routine scans for low-back pain do not improve outcomes 3
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
For the quantitative in vitro determination of Lipase in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Ammonia in plasma...
Medicine Products: